STORY SUMMARY
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Experimental drug invika halts progression of refractory tumors by selectively stimulating tumor-fighting T cells.
This is a brief summary of reporting from NIH News Releases. Read the original for the full article and context.